Importantly, our study revealed that combining IFITM3 and MHC-I expression further improved the predictive accuracy, suggesting that this dual-marker approach could offer a more comprehensive predictor of immunotherapy outcomes in SCLC patients. This evidence concerns the gene IFITM3 and small cell lung carcinoma.